Trial Profile
A Phase I/II Study of Sorafenib in Combination With Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN06-111.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Topotecan (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Mar 2016 According to ClinicalTrials.gov record, dose of Topotecan has been changed from 4mg/m2 to 3.5mg/m2.
- 24 Feb 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 05 Aug 2009 Planned end date changed from 1 Sep 2009 to 1 Feb 2010 as reported by ClinicalTrials.gov.